BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29277288)

  • 1. Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent.
    Kalkman DN; Woudstra P; Menown IBA; Tijssen JG; Beijk MAM; de Winter RJ;
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):373-375. PubMed ID: 29277288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry.
    Woudstra P; Kalkman DN; den Heijer P; Menown IB; Erglis A; Suryapranata H; Arkenbout KE; Iñiguez A; van 't Hof AW; Muller P; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1127-34. PubMed ID: 27209254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration.
    de Winter RJ; Chandrasekhar J; Kalkman DN; Aquino MB; Woudstra P; Beijk MA; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Mehran R; ;
    JACC Cardiovasc Interv; 2018 Oct; 11(19):1969-1978. PubMed ID: 30286855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
    Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
    JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry.
    Kalkman DN; Kerkmeijer LS; Woudstra P; Menown IBA; Suryapranata H; den Heijer P; Iñiguez A; van 't Hof AWJ; Erglis A; Arkenbout KE; Muller P; Koch KT; Tijssen JG; Beijk MAM; de Winter RJ
    Catheter Cardiovasc Interv; 2019 Sep; 94(3):342-347. PubMed ID: 30565371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
    Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
    EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
    Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome.
    Kalkman DN; Woudstra P; Lu H; Menown IBA; den Heijer P; Suryapranata H; Iñiguez A; Arkenbout KE; Van't Hof AWJ; Muller P; Erglis A; Tijssen JG; Beijk MAM; de Winter RJ
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):E31-E37. PubMed ID: 28145609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
    Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry.
    Colombo A; Chandrasekhar J; Aquino M; Ong TK; Sartori S; Baber U; Lee M; Iniguez A; Hajek P; Borisov B; Atzev B; Den Heijer P; Coufal Z; Hudec M; Mates M; Snyder C; Moalem K; Morrell D; Elmore F; Rowland S; Mehran R;
    Int J Cardiol; 2019 May; 283():67-72. PubMed ID: 30826192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Godino C; Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Perfetti G; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Fabbiocchi F; Reimers B; Bartorelli A; Colombo A
    Int J Cardiol; 2019 Sep; 290():52-58. PubMed ID: 30917900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-month outcomes of patients unsuitable for prolonged DAPT presenting with an acute coronary syndrome and treated with polymer-free biolimus A9 drug-coated stents.
    Kinnaird T; Abdul F; Hailan A; Sheikh A; Hinton J; Yazji K; Elangovan S; Yousef A; Gallagher S; Choudhury A; Anderson R; O'Kane P; Smith D
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):1220-1228. PubMed ID: 30244504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent.
    Liu Y; Zhang Y; Li Y; Qi T; Pan D; Wang H; Liu C; Ma D; Fang Z; Zhang R; Mou F; Tao L;
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():658-664. PubMed ID: 31961057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
    Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent.
    Haude M; Lee SWL; Worthley SG; Silber S; Verheye S; Rosli MA; Botelho R; Sim KH; Abizaid A; Mehran R;
    Catheter Cardiovasc Interv; 2020 May; 95(6):1076-1084. PubMed ID: 31489742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis.
    Jaguszewski M; Aloysius R; Wang W; Bezerra HG; Hill J; De Winter RJ; Karjalainen PP; Verheye S; Wijns W; Lüscher TF; Joner M; Costa M; Landmesser U
    JACC Cardiovasc Interv; 2017 Mar; 10(5):489-499. PubMed ID: 28279316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.